Top Heal Care Stocks To Invest In Right Now

Top Heal Care Stocks To Invest In Right Now: ACADIA Pharmaceuticals Inc.(ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson's disease psychosis. It is also developing AGN-XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development in collaboration with Meiji Seika Kaisha, Ltd. In addition, ACADIA Pharmaceuticals Inc. is developing two preclinical programs in the area of Parkinson?s disease. The product candidates in the company?s pipeline emanate from discoveries made using its proprietary drug discovery platform. The company was founded in 1993 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Sean Williams]

  ACADIA Pharmaceuticals (NASDAQ: ACAD  ) added on 63% since last Friday, following an announcement that the FDA will allow it to file an accelerated new drug application for its Parkinson's disease anti-psychosis drug, Pimavanserin. ACADIA's drug met the primary endpoint of demonstrating highly significant anti-psychotic activity and the secondary endpoint of increased motoric tolerability in its late-stage trial, which provided more than enough evidence for the FDA to give the company the go-ahead to skip another confirmatory trial. Pimavanserin's chances for approval definitely got a boost, but ACADIA's valuation certainly is giving me cause for concern.

• [By Sean Williams]

  What: Shares of ACADIA Pharmaceuticals (NASDAQ: ACAD  ) , a clinical-stage biopharmaceutical company, skyrocketed as much as 54% after it announced that it was filing an accelerated new drug applic! ation for Pimavanserin after discussions with the Food and Drug Administration.

• [By Rick Munarriz]

  Tuesday
  ACADIA Pharmaceuticals (NASDAQ: ACAD  ) checks in on Tuesday. The biotech company's lead candidate is pimavanserin, a promising drug that's in the third and final phase of clinical development as a treatment for Parkinson's disease psychosis. Naturally, investors see red ink here, but analysts do see the quarterly deficit narrowing this time around.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/top-heal-care-stocks-to-invest-in-right-now-3.html